- Home
- COEP
as 05-20-2024 1:31pm EST
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
| Founded: | 2017 | Country: | United States |
| Employees: | 7 | City: | WEXFORD |
| Market Cap: | 13.0M | IPO Year: | N/A |
| Target Price: | $6.50 | AVG Volume (30 days): | 253.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.28 - $2.19 | Next Earning Date: | 05-10-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Latest Coeptis Therapeutics Holdings Inc. News
COEP Breaking Stock News: Dive into COEP Ticker-Specific Updates for Smart Investing
PR Newswire
12 days ago
Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024
PR Newswire
18 days ago
Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
PR Newswire
2 months ago
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award
Argus Research
2 months ago
Daily – Vickers Top Insider Picks for 03/21/2024
Argus Research
2 months ago
Daily – Vickers Top Insider Picks for 03/20/2024
Argus Research
2 months ago
Daily – Vickers Top Insider Picks for 03/19/2024
Argus Research
2 months ago
Daily – Vickers Top Insider Picks for 03/18/2024
Argus Research
2 months ago